NARCOLEPSY TYPE 2
Clinical trials for NARCOLEPSY TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY TYPE 2 trials appear
Sign up with your email to follow new studies for NARCOLEPSY TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for sleep disorder patients: ORX750 enters long-term safety trial
Disease control Recruiting nowThis study looks at the long-term safety and effects of a drug called ORX750 in people with narcolepsy (types 1 and 2) or idiopathic hypersomnia. About 90 participants who finished a previous ORX750 trial will take the drug openly for an extended period. Researchers will monitor …
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated May 26, 2026 06:01 UTC
-
New sleep disorder drug tested for Long-Term safety and effectiveness
Disease control Recruiting nowThis study looks at the long-term safety and how well the drug ALKS 2680 works for people with narcolepsy type 1, type 2, or idiopathic hypersomnia. It is for those who have already finished a related earlier study. Participants will take ALKS 2680 tablets and be monitored for si…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New orexin mimic could wake up sleep disorder treatment
Symptom relief Recruiting nowThis study tests a new drug called ORX750 (cleminorexton) that mimics a natural brain protein, orexin, which helps keep people awake. It is for adults with narcolepsy type 1, type 2, or idiopathic hypersomnia who struggle with severe daytime sleepiness. The goal is to see if the …
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Symptom relief
Last updated May 26, 2026 06:07 UTC
-
New pill aims to fight daytime sleepiness in narcolepsy
Symptom relief Recruiting nowThis study tests a new medication, ALKS 2680, to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the drug or a placebo. The main goal is to measure how well they can stay awake during the day after 12 weeks of t…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 26, 2026 06:00 UTC
-
New pill mimics brain chemical to fight daytime sleepiness
Symptom relief Recruiting nowThis study tests an experimental drug called TAK-360 in 88 adults with narcolepsy type 2, a condition that causes severe daytime sleepiness. TAK-360 acts like a natural brain chemical that promotes wakefulness. The main goals are to check the drug's safety and see if it helps peo…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Takeda • Aim: Symptom relief
Last updated May 22, 2026 13:54 UTC
-
Spain launches first nationwide narcolepsy census
Knowledge-focused Recruiting nowThis study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. The study does…
Matched conditions: NARCOLEPSY TYPE 2
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 26, 2026 06:06 UTC